vs
Side-by-side financial comparison of AerSale Corp (ASLE) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
AerSale Corp is the larger business by last-quarter revenue ($90.9M vs $86.8M, roughly 1.0× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -4.0%). AerSale Corp produced more free cash flow last quarter ($9.8M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 0.2%).
AerSale, Inc. is a Doral, Florida-based global supplier of aftermarket commercial jet aircraft, engines, used materials, and aeronautical engineering services to passenger and cargo airlines, government, multinational original equipment manufacturers, and independent MROs. AerSale is a member of the Aircraft Fleet Recycling Association.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
ASLE vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $90.9M | $86.8M |
| Net Profit | $5.4M | — |
| Gross Margin | 34.1% | 67.4% |
| Operating Margin | 7.8% | -84.7% |
| Net Margin | 5.9% | — |
| Revenue YoY | -4.0% | 17.7% |
| Net Profit YoY | 99.7% | — |
| EPS (diluted) | $0.10 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $90.9M | $86.8M | ||
| Q3 25 | $71.2M | $67.5M | ||
| Q2 25 | $107.4M | $60.0M | ||
| Q1 25 | $65.8M | $49.3M | ||
| Q4 24 | $94.7M | $73.7M | ||
| Q3 24 | $82.7M | $58.6M | ||
| Q2 24 | $77.1M | $31.1M | ||
| Q1 24 | $90.5M | $715.0K |
| Q4 25 | $5.4M | — | ||
| Q3 25 | $-120.0K | $-91.3M | ||
| Q2 25 | $8.6M | $-111.7M | ||
| Q1 25 | $-5.3M | $-116.2M | ||
| Q4 24 | $2.7M | — | ||
| Q3 24 | $509.0K | $-83.5M | ||
| Q2 24 | $-3.6M | $-97.1M | ||
| Q1 24 | $6.3M | $-113.0M |
| Q4 25 | 34.1% | 67.4% | ||
| Q3 25 | 30.2% | 43.0% | ||
| Q2 25 | 32.9% | 5.5% | ||
| Q1 25 | 27.3% | -0.8% | ||
| Q4 24 | 31.4% | 68.7% | ||
| Q3 24 | 28.6% | 46.2% | ||
| Q2 24 | 28.2% | -0.8% | ||
| Q1 24 | 31.8% | — |
| Q4 25 | 7.8% | -84.7% | ||
| Q3 25 | 4.0% | -140.7% | ||
| Q2 25 | 11.7% | -189.8% | ||
| Q1 25 | -10.1% | -245.8% | ||
| Q4 24 | 5.2% | -117.5% | ||
| Q3 24 | 2.4% | -152.1% | ||
| Q2 24 | -2.4% | -327.6% | ||
| Q1 24 | 5.2% | -16464.6% |
| Q4 25 | 5.9% | — | ||
| Q3 25 | -0.2% | -135.3% | ||
| Q2 25 | 8.0% | -186.2% | ||
| Q1 25 | -8.0% | -235.5% | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 0.6% | -142.7% | ||
| Q2 24 | -4.7% | -312.2% | ||
| Q1 24 | 6.9% | -15800.8% |
| Q4 25 | $0.10 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $0.18 | $-0.33 | ||
| Q1 25 | $-0.10 | $-0.36 | ||
| Q4 24 | $0.05 | $-0.24 | ||
| Q3 24 | $0.01 | $-0.28 | ||
| Q2 24 | $-0.07 | $-0.34 | ||
| Q1 24 | $0.12 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.4M | $297.0M |
| Total DebtLower is stronger | $1.3M | — |
| Stockholders' EquityBook value | $424.4M | $698.6M |
| Total Assets | $640.5M | $913.2M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.4M | $297.0M | ||
| Q3 25 | $5.3M | $300.8M | ||
| Q2 25 | $5.7M | $301.2M | ||
| Q1 25 | $4.7M | $359.7M | ||
| Q4 24 | $4.7M | $323.8M | ||
| Q3 24 | $9.8M | $397.5M | ||
| Q2 24 | $4.3M | $412.5M | ||
| Q1 24 | $2.6M | $356.2M |
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $907.0K | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $1.2M | — | ||
| Q3 24 | $376.0K | — | ||
| Q2 24 | $522.0K | — | ||
| Q1 24 | $3.5M | — |
| Q4 25 | $424.4M | $698.6M | ||
| Q3 25 | $417.1M | $702.3M | ||
| Q2 25 | $415.9M | $698.5M | ||
| Q1 25 | $406.5M | $767.9M | ||
| Q4 24 | $455.6M | $710.4M | ||
| Q3 24 | $451.5M | $773.5M | ||
| Q2 24 | $449.8M | $768.5M | ||
| Q1 24 | $452.0M | $680.0M |
| Q4 25 | $640.5M | $913.2M | ||
| Q3 25 | $646.3M | $904.9M | ||
| Q2 25 | $646.7M | $907.4M | ||
| Q1 25 | $646.1M | $966.7M | ||
| Q4 24 | $604.7M | $910.4M | ||
| Q3 24 | $601.5M | $991.1M | ||
| Q2 24 | $598.7M | $964.3M | ||
| Q1 24 | $571.7M | $869.8M |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.4M | $-52.6M |
| Free Cash FlowOCF − Capex | $9.8M | $-61.9M |
| FCF MarginFCF / Revenue | 10.8% | -71.3% |
| Capex IntensityCapex / Revenue | 1.7% | 10.7% |
| Cash ConversionOCF / Net Profit | 2.11× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-29.1M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.4M | $-52.6M | ||
| Q3 25 | $-8.9M | $-78.7M | ||
| Q2 25 | $19.8M | $-67.4M | ||
| Q1 25 | $-45.2M | $-103.7M | ||
| Q4 24 | $37.5M | $-73.3M | ||
| Q3 24 | $10.4M | $-59.0M | ||
| Q2 24 | $-15.3M | $-98.4M | ||
| Q1 24 | $-21.5M | $-122.3M |
| Q4 25 | $9.8M | $-61.9M | ||
| Q3 25 | $-9.8M | $-89.5M | ||
| Q2 25 | $18.6M | $-74.9M | ||
| Q1 25 | $-47.6M | $-109.9M | ||
| Q4 24 | $32.3M | $-77.5M | ||
| Q3 24 | $8.9M | $-61.3M | ||
| Q2 24 | $-18.9M | $-98.9M | ||
| Q1 24 | $-25.0M | $-126.5M |
| Q4 25 | 10.8% | -71.3% | ||
| Q3 25 | -13.8% | -132.7% | ||
| Q2 25 | 17.3% | -124.9% | ||
| Q1 25 | -72.4% | -222.8% | ||
| Q4 24 | 34.0% | -105.1% | ||
| Q3 24 | 10.7% | -104.6% | ||
| Q2 24 | -24.6% | -317.9% | ||
| Q1 24 | -27.7% | -17685.3% |
| Q4 25 | 1.7% | 10.7% | ||
| Q3 25 | 1.3% | 16.1% | ||
| Q2 25 | 1.1% | 12.4% | ||
| Q1 25 | 3.7% | 12.6% | ||
| Q4 24 | 5.6% | 5.7% | ||
| Q3 24 | 1.9% | 3.9% | ||
| Q2 24 | 4.7% | 1.4% | ||
| Q1 24 | 3.9% | 583.4% |
| Q4 25 | 2.11× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.31× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 13.89× | — | ||
| Q3 24 | 20.52× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -3.42× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASLE
| Products | $57.8M | 64% |
| Maintenance | $23.2M | 26% |
| Leasing Arrangements | $9.9M | 11% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
